GlassScriptPhysician profile
Joseph H Richard
NPI 1700892346
$7,835.00
in general payments reported to CMS, 2019-2025
27 companies · $2,518 in 2025
The $2,518 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,189 · 2022: $1,422 · 2023: $1,477 · 2024: $1,229 · 2025: $2,518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,140 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,140.39 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,212.58 | 2021-2025 | |
| Janssen Biotech, INC. | $1,498.98 | 2021-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $540.04 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Madrigal Pharmaceuticals | $445.45 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $398.75 | 2021-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $355.99 | 2021-2024 | Linzess |
| Celgene Corporation | $300.15 | 2021-2024 | Zeposia |
| Genzyme Corporation | $275.16 | 2024-2025 | |
| Ardelyx, INC. | $251.57 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $228.84 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Regeneron Healthcare Solutions, INC. | $176.40 | 2025 | Dupixent |
| Janssen Scientific Affairs, LLC | $157.18 | 2022-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $136.04 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $128.65 | 2021-2025 | |
| Evoke Pharma, INC. | $123.50 | 2022-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $117.31 | 2022-2024 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $111.09 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.18 | 2022-2023 | Cyltezo |
| Intercept Pharmaceuticals, INC. | $64.84 | 2021-2023 | Ocaliva |
| Pfizer INC. | $59.04 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $47.92 | 2025 | Vowst, Zenpep |
| Celltrion USA INC. | $23.38 | 2024 | Zymfentra |
| Novo Nordisk INC | $20.34 | 2025 | Saxenda, Wegovy |
| Alnylam Pharmaceuticals INC. | $16.05 | 2024 | Givlaari |
| Medtronic, INC. | $15.82 | 2022 | |
| Braintree Laboratories, INC. | $15.57 | 2022 | |
| Daiichi Sankyo INC. | $15.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Richard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.